For example, while PDE-5 inhibitors prevent the degradation of cGMP and have demonstrated efficacy in PAH [1], [4], their effects are dependent on the presence of an intact NO–sGC–cGMP axis [5]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.